Собственный опыт использования пероральной формы винорелбина


Цитировать

Полный текст

Аннотация

Об авторах

Н Ю Добровольская

ФГБУ Российский научный центр рентгенорадиологии Минздрава РФ, Москва

ФГБУ Российский научный центр рентгенорадиологии Минздрава РФ, Москва

С А Большакова

ФГБУ Российский научный центр рентгенорадиологии Минздрава РФ, Москва

ФГБУ Российский научный центр рентгенорадиологии Минздрава РФ, Москва

Ю М Бычков

ФГБУ Российский научный центр рентгенорадиологии Минздрава РФ, Москва

ФГБУ Российский научный центр рентгенорадиологии Минздрава РФ, Москва

Р Д Квиникадзе

ФГБУ Российский научный центр рентгенорадиологии Минздрава РФ, Москва

ФГБУ Российский научный центр рентгенорадиологии Минздрава РФ, Москва

Ю А Понкратова

ФГБУ Российский научный центр рентгенорадиологии Минздрава РФ, Москва

ФГБУ Российский научный центр рентгенорадиологии Минздрава РФ, Москва

Список литературы

  1. Liu G, Franssen E, Fitch MI et al. Patients preferences for oral vs. intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-5.
  2. Binet S, Chaineau E, Fellous A et al. Immunofluorescence study of the action of navelbine, vincristine on mitotic and axonal microtubules. Int J Cancer 1990; 46: 262-6.
  3. Marty M, Fumoleau P, Adenis A et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001; 12: 1643-9.
  4. Varoli P, Nguyen L, Tranchard B et al. A simultaneous oral/intravenous population pharmacokinetics model for vinorelbine. Eur J Clin Pharmacol 2002; 58: 467-76.
  5. Dipierre A, Chastang Cl, Quoix E et al. Vinorelbine versus vinorelbine plus cisplatin in advanced NSCLC: a randomized trial. Ann of Oncol 1994; 5: 37-42.
  6. Le Chevalier T. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin vs. vinorelbine alone in advanced non-small cell lung cancer: a results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12 (12): 360-7.
  7. Crawford J, O'Rourke M, Schiller JH et al. Randomized trial of the vinorelbine compared with fluorouracil plus leucovorin on patients with stage IV NSCLC. J Clin Oncol 1996; 14 (10): 2774-84.
  8. Fumoleau P, Delgao FM, Delozier T et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1993; 11: 1245-332.
  9. Garcia-Gonde J et al. Phase II trial of weekly in vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994; 5: 854-7.
  10. Bruno S, Lira-Peurto V, Mickiewicz F et al. Phase II trial with navelbine in the treatment of advanced breast cancer patients. Ann Oncol 1992; 3 (1): 126-9.
  11. Weber B, Vogel C, Jones et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995; 13: 2722-30.
  12. Romero A, Rabinovitch MG, Vallero C. Vinorelbine as first line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994; 12: 336-41.
  13. Terenziani M, Demicheli R, Brambilla C et al. Vinorelbine: an active, non-cross-resistant drug in advanced breast cancer - results from a phase II study. Breast Cancer Research Treatment 1996; 39: 285-91.
  14. Vogel C, O'Rourke M, Winer et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years old. Ann Oncol 1999; 10: 397-402.
  15. Gligorov J, Beerblock K, Selle F et al. Capecitabine and oral vinorelbine in metastatic breast cancer: preliminary experience. Proc Am Soc Clin Oncol 2003; 22. Abstr. 351.
  16. Anton A, Lluch A, Casado A et al. Phase I-II study of oral vinorelbine (NVBO) and capecitabine (X) in metastatic breast cancer (MBC): results of the phase I trial. J Clin Oncol 2008; 26 (15s): 67s. Abstr. 1105.
  17. Gil-Delgado M, Rocher M, Boostandoost E, Khayat D. First step of oral vinorelbine and capecitabine combination in advanced breast cancer patients: feasibility study. J Clin Oncol 2008; 26: 1135 (15s).
  18. Delcambre C, Veyret C, Levy C et al. A phase I-II study of capecitabine (Xeloda®) combined with oral vinorelbine as first- or second-line therapy on locally advanced or metastatic breast cancer (MBC). Proc San Antonio Breast Cancer Symposium 2005. Abstr. 1081.
  19. Kellokumpu-Lehtinen PL, Sunela K, Lehtinen I et al. Finished Breast Cancer Group. A phase I study of an all oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 2006; 17: 401-5.
  20. Nole F, Catania C, Sanna G et al. Dose-finding and pharmacokinetic study of an all oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2006; 17: 322-9.
  21. Finek J, Holubec L Jr, Svoboda T et al. A phase II trial of oral vinorelbine and capecitabine in antracycline pretreated patients with metastatic breast cancer. Anticancer Res 2009; 29 (2): 667-70.
  22. Nole F, Grivellari D, Mattioli R et al. Phase II study of an all oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 2009; 64 (4): 673-80.
  23. Tubiana-Mathieu N, Bougnoux P, Becquart D et al. All oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an international phase II trial. Br J Cancer 2009; 101 (2): 232-7.
  24. Jones A, O'Brien M, Sommer H et al. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 2010; 65 (4): 755-63.
  25. Kowalski DM, Krzakowski MJ, Zajda K et al. Oral vinorelbine (NVBo) at 3-weekly flat-dose intakes (FDI) as single agent or with cisplatin (CDDP) concomitantly with thoracic radiotherapy (RT) in stage III NSCLC: Escalation-dose phase I trial results. ASCO Meeting. Abstr. 2011, abstr. 7045.
  26. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.

© ООО "Консилиум Медикум", 2012

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial 4.0 International License.
 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах